Mazdutide's Dual Agonism: A New Path for Type 2 Diabetes in Chinese Adults?

Type 2 diabetes and obesity frequently coexist, creating a complex metabolic environment that increases the risk of cardiovascular events, renal disease, and other complications. Effective management requires therapies that can simultaneously improve glycemic control and induce substantial weight loss. The GLP-1 receptor agonist class has demonstrated success in this area, but the addition of glucagon receptor agonism in mazdutide represents an evolution in this therapeutic strategy.¹

The efficacy and safety of mazdutide in predominantly Chinese adults with type 2 diabetes and/or obesity were recently assessed in a systematic review and meta-analysis, which pooled data from multiple trials.¹ This analysis, published in Diabetes, Obesity and Metabolism, included 1,189 participants from four randomized controlled trials. A separate, more focused study, published in Nature, specifically examined mazdutide versus placebo in Chinese adults with type 2 diabetes, providing granular detail on this population.²

What the trials actually measured

The primary endpoints across these studies consistently focused on changes in glycated hemoglobin (HbA1c) and body weight from baseline. Secondary endpoints included changes in fasting plasma glucose (FPG), lipid profiles (total cholesterol, LDL-C, HDL-C, triglycerides), and liver enzymes (ALT, AST). Safety assessments included the incidence of adverse events (AEs), serious AEs, and withdrawals due to AEs. The trials typically involved treatment durations ranging from 12 to 24 weeks, comparing various doses of mazdutide (e.g., 3 mg, 4 mg, 6 mg) against placebo.^1,2

Patients enrolled in these trials were adults with type 2 diabetes, many of whom also had overweight or obesity (BMI ≥24 kg/m² for Chinese populations). The mean baseline HbA1c generally ranged from 7.9% to 8.5%, indicating suboptimal glycemic control despite existing treatments. Baseline body weight averaged between 80 kg and 90 kg. These were typical patients seen in general practice, often struggling with both conditions.^1,2

The numbers

Mazdutide delivered a clear benefit across both glycemic and weight parameters. The meta-analysis showed that mazdutide significantly reduced HbA1c compared to placebo. For the 6 mg dose, the mean difference in HbA1c reduction was -2.05% (95% CI, -2.31 to -1.79), a substantial improvement. Even lower doses, such as 4 mg, produced a mean reduction of -1.78% (95% CI, -2.04 to -1.52). These are not marginal shifts; they represent a meaningful impact on glycemic control.¹

Body weight reductions were equally impressive. The 6 mg dose of mazdutide led to a mean body weight reduction of -10.43 kg (95% CI, -12.35 to -8.51) compared to placebo. The 4 mg dose achieved a reduction of -8.31 kg (95% CI, -9.99 to -6.63). These weight losses are clinically significant, approaching the levels seen with bariatric surgery for some patients. The dual agonism appears to be driving these effects, with glucagon receptor activation potentially contributing to increased energy expenditure and direct fat loss.¹

Beyond the primary endpoints, mazdutide also improved several secondary metabolic markers. Fasting plasma glucose decreased significantly, with a mean difference of -3.32 mmol/L (95% CI, -3.88 to -2.76) for the 6 mg dose. Total cholesterol, LDL-C, and triglycerides all saw reductions, while HDL-C levels increased. Liver enzymes, specifically ALT and AST, also decreased, suggesting a positive impact on hepatic steatosis, a common comorbidity in this patient group.¹ This comprehensive metabolic improvement is a key differentiator for dual agonists, as discussed in our previous coverage on GLP-1 receptor agonist use in youth with type 2 diabetes.¹

Safety and tolerability

The safety profile of mazdutide was consistent with other GLP-1 receptor agonists, primarily involving gastrointestinal adverse events. Nausea, vomiting, diarrhea, and constipation were the most frequently reported AEs. Nausea occurred in 35.5% of mazdutide recipients compared to 12.3% of placebo recipients. Vomiting was reported in 17.7% versus 4.9%, and diarrhea in 16.1% versus 10.7%. These events were generally mild to moderate in severity and transient, often resolving with continued treatment.¹

Still, the incidence of withdrawals due to adverse events was higher in the mazdutide groups, at 9.7%, compared to 2.5% in the placebo group. This suggests that while generally tolerable, some patients may struggle with the initial gastrointestinal side effects. Serious adverse events were rare and balanced between mazdutide and placebo groups, with no new safety signals identified. Hypoglycemia rates were low, particularly in patients not on insulin or sulfonylureas, which is reassuring for a potent glucose-lowering agent.¹

The trials were predominantly conducted in Chinese adults, which is an an important consideration. While the mechanism of action for mazdutide is universal, metabolic responses and tolerability can sometimes vary across ethnic populations. Whether these exact magnitudes of effect will translate directly to European populations remains to be seen, though the general trend of efficacy is likely to hold. The relatively short duration of some trials (12-24 weeks) also means long-term cardiovascular outcomes data are not yet available, a critical piece of information for any new diabetes therapy. This is a common limitation for new agents, and future trials will need to address this gap, similar to the discussions around key diabetes trials to watch for long-term data.^1,2

The dual agonism of mazdutide, targeting both GLP-1 and glucagon receptors, offers a distinct advantage over single-agent GLP-1 receptor agonists. Glucagon, traditionally known for its glucose-raising effects, also plays a role in energy expenditure and fat metabolism. By activating both receptors, mazdutide appears to harness these complementary pathways, leading to more pronounced effects on weight loss and metabolic parameters. This mechanism could be particularly beneficial for patients with significant obesity and fatty liver disease.¹ Clinicians looking for a comprehensive overview of diabetes management, including newer agents, might find the Oxford Handbook of Endocrinology and Diabetes (4th ed) a useful reference.

The data presented here are compelling for the Chinese adult population. Mazdutide offers a powerful tool for clinicians managing type 2 diabetes, especially when obesity is a significant factor. The magnitude of HbA1c and weight reduction positions it as a strong contender in the evolving market of diabetes and obesity pharmacotherapy. But, as with all new agents, careful patient selection and monitoring for gastrointestinal side effects will be essential for successful implementation in clinical practice. The need for long-term cardiovascular safety data is the next hurdle for mazdutide to clear.^1,2